Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 526783 | NSE: | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Dr Agarwals Eye Hospital Ltd is a good quality company.
The key valuation ratios of Dr Agarwals Eye Hospital Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Dr Agarwals Eye Hospital Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 11.6% | 17.1% | 5.9% | 19.7% | 17.4% | 23.5% | 27.2% | 4.6% | 31.1% | 31.9% | - |
| Value Creation Index ⓘ | -0.2 | 0.2 | -0.6 | 0.4 | 0.2 | 0.7 | 1.0 | -0.7 | 1.2 | 1.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 113 | 118 | 137 | 149 | 153 | 170 | 176 | 140 | 201 | 268 | 306 |
| Sales YoY Gr. | - | 4.9% | 15.6% | 8.8% | 3.2% | 10.9% | 3.5% | -20.5% | 43.9% | 33.1% | - |
| Adj EPS ⓘ | 5.5 | 12.1 | -0.1 | 16.2 | 14.5 | 25.3 | 28.7 | -3 | 51 | 78.7 | 100.5 |
| YoY Gr. | - | 119.2% | -100.8% | NA | -10.5% | 74.2% | 13.3% | -110.5% | NA | 54.4% | - |
| BVPS (₹) ⓘ | 40.4 | 50.6 | 49.8 | 62.6 | 74.6 | 97 | 119.4 | 116.3 | 166.3 | 241.2 | 311.6 |
| Adj Net Profit ⓘ | 2.6 | 5.7 | 0 | 7.6 | 6.8 | 11.9 | 13.5 | -1.4 | 24 | 37 | 47 |
| Cash Flow from Ops. ⓘ | 11.9 | 13.7 | 17.4 | 20.1 | 18.6 | 25.1 | 38.6 | 33.9 | 56.7 | 69.6 | - |
| Debt/CF from Ops. ⓘ | 2.3 | 2 | 1.8 | 1.2 | 1 | 1 | 0.5 | 0.6 | 0.6 | 0.6 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 10.1% | 11.8% | 15% | 33.1% | ||||
| Adj EPS ⓘ | 34.3% | 40.2% | 40% | 54.4% | ||||
| BVPSⓘ | 22% | 26.5% | 26.4% | 45% | ||||
| Share Price | 48.6% | 59.4% | 123.4% | 204.3% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 15 | 26.6 | -0.2 | 28.9 | 21.2 | 29.5 | 26.5 | -2.6 | 36.1 | 38.6 | 36.4 |
| Op. Profit Mgn % ⓘ | 9.4 | 12.8 | 11.1 | 15.2 | 15.9 | 17.6 | 26.9 | 21.4 | 29.2 | 28.3 | 28 |
| Net Profit Mgn % ⓘ | 2.3 | 4.8 | -0 | 5.1 | 4.5 | 7 | 7.7 | -1 | 11.9 | 13.8 | 15.4 |
| Debt to Equity ⓘ | 1.5 | 1.1 | 1.3 | 0.8 | 0.5 | 0.5 | 0.3 | 0.4 | 0.4 | 0.4 | - |
| Working Cap Days ⓘ | 117 | 118 | 114 | 112 | 117 | 124 | 131 | 150 | 103 | 92 | 31 |
| Cash Conv. Cycle ⓘ | -6 | -13 | -12 | -17 | -22 | -21 | -9 | -13 | -29 | -31 | -4 |
Return on Equity has increased versus last 3 years average to 36.40%
Sales growth is growing at healthy rate in last 3 years 15.04%
Net Profit is growing at healthy rate in last 3 years 40.00%
Sales growth is good in last 4 quarters at 20.44%
No data to display
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 100.5 | - |
| TTM Sales (₹ Cr.) | 306 | - |
| BVPS (₹.) ⓘ | 311.6 | - |
| Reserves (₹ Cr.) ⓘ | 142 | - |
| P/BV ⓘ | 10.67 | - |
| PE ⓘ | 33.05 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 1130.00 / 3550.00 |
| All Time Low / High (₹) | 2.10 / 3550.00 |
| Market Cap (₹ Cr.) | 1,562 |
| Equity (₹ Cr.) | 4.7 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 84.5 |
| Pledged * | 99.14 | 98.44 | 59.76 | 59.84 | 99.80 | 99.80 | 99.80 | 39.95 | 39.95 | 0.00 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 113 | 118 | 137 | 149 | 153 | 170 | 176 | 140 | 201 | 268 |
| Operating Expenses ⓘ | 102 | 103 | 121 | 126 | 129 | 140 | 129 | 110 | 143 | 192 |
| Manufacturing Costs | 25 | 37 | 45 | 44 | 45 | 50 | 51 | 46 | 62 | 83 |
| Material Costs | 30 | 16 | 18 | 18 | 18 | 19 | 22 | 16 | 23 | 30 |
| Employee Cost | 23 | 23 | 30 | 32 | 32 | 34 | 36 | 32 | 39 | 53 |
| Other Costs ⓘ | 24 | 27 | 28 | 31 | 34 | 37 | 20 | 15 | 19 | 26 |
| Operating Profit ⓘ | 10 | 15 | 15 | 22 | 24 | 30 | 47 | 30 | 59 | 76 |
| Operating Profit Margin (%) | 9.1% | 12.8% | 11.1% | 15.0% | 15.8% | 17.6% | 26.8% | 21.3% | 29.1% | 28.2% |
| Other Income ⓘ | 3 | 0 | 0 | 2 | 2 | 2 | 3 | 2 | 1 | 2 |
| Interest ⓘ | 4 | 4 | 5 | 4 | 3 | 4 | 9 | 7 | 7 | 8 |
| Depreciation ⓘ | 6 | 6 | 11 | 9 | 10 | 11 | 21 | 19 | 20 | 20 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 4 | 5 | 0 | 11 | 13 | 17 | 20 | 6 | 32 | 49 |
| Tax ⓘ | 1 | 0 | -1 | 4 | 7 | 6 | 6 | 7 | 8 | 12 |
| Profit After Tax | 2 | 6 | 0 | 7 | 7 | 12 | 14 | -1 | 24 | 37 |
| PAT Margin (%) | 2.2% | 4.8% | 0.0% | 4.9% | 4.4% | 7.0% | 7.8% | -1.0% | 12.0% | 13.8% |
| Adjusted EPS (₹) | 5.2 | 12.1 | 0.1 | 15.6 | 14.4 | 25.4 | 29.1 | -3.1 | 51.3 | 78.6 |
| Dividend Payout Ratio (%) | 23% | 10% | 1,024% | 10% | 8% | 6% | 0% | 0% | 6% | 4% |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 19 | 24 | 23 | 29 | 35 | 46 | 56 | 55 | 78 | 113 |
| Share Capital ⓘ | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves ⓘ | 14 | 19 | 19 | 25 | 30 | 41 | 51 | 50 | 73 | 109 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 21 | 23 | 24 | 16 | 10 | 18 | 13 | 17 | 27 | 40 |
| Long Term Debt | 12 | 15 | 18 | 13 | 5 | 13 | 8 | 10 | 21 | 36 |
| Short Term Debt | 9 | 8 | 6 | 3 | 5 | 5 | 5 | 7 | 6 | 4 |
| Trade Payables | 11 | 16 | 18 | 14 | 18 | 15 | 14 | 18 | 26 | 27 |
| Others Liabilities ⓘ | 16 | 4 | 19 | 22 | 33 | 41 | 83 | 78 | 203 | 242 |
| Total Liabilities ⓘ | 67 | 67 | 84 | 81 | 96 | 120 | 166 | 167 | 333 | 422 |
Fixed Assets | ||||||||||
| Gross Block | 68 | 75 | 87 | 37 | 49 | 78 | 138 | 158 | 295 | 365 |
| Accumulated Depreciation | 42 | 48 | 53 | 4 | 13 | 23 | 44 | 62 | 81 | 104 |
| Net Fixed Assetsⓘ | 26 | 26 | 34 | 33 | 36 | 55 | 94 | 96 | 214 | 260 |
| CWIP ⓘ | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 26 | 62 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 8 | 10 | 10 | 6 | 7 | 6 | 8 | 5 | 6 | 6 |
| Trade Receivables | 6 | 6 | 9 | 7 | 7 | 9 | 7 | 9 | 9 | 10 |
| Cash Equivalents | 3 | 2 | 2 | 3 | 2 | 5 | 7 | 22 | 29 | 28 |
| Others Assetsⓘ | 24 | 22 | 28 | 31 | 40 | 45 | 51 | 36 | 49 | 55 |
| Total Assets ⓘ | 67 | 67 | 84 | 81 | 96 | 120 | 166 | 167 | 333 | 422 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 12 | 14 | 17 | 20 | 19 | 25 | 39 | 34 | 57 | 70 |
| PBT ⓘ | 4 | 5 | 0 | 7 | 13 | 17 | 20 | 6 | 32 | 49 |
| Adjustment ⓘ | 10 | 10 | 15 | 15 | 13 | 13 | 28 | 27 | 27 | 27 |
| Changes in Working Capital ⓘ | -2 | 1 | 5 | 1 | -2 | 3 | -3 | 4 | 6 | 5 |
| Tax Paid ⓘ | 0 | -2 | -3 | -3 | -5 | -8 | -7 | -3 | -9 | -12 |
| Cash Flow From Investing Activity ⓘ | -11 | -10 | -17 | -8 | -11 | -25 | -17 | -11 | -46 | -71 |
| Capex | -11 | -11 | -17 | -8 | -11 | -25 | -17 | -11 | -46 | -71 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | -1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | -3 | -5 | 0 | -12 | -8 | 2 | -20 | -8 | -4 | 0 |
| Net Proceeds from Shares ⓘ | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -1 | 0 | 6 | -5 | -7 | 6 | -6 | 2 | 11 | 20 |
| Interest Paid ⓘ | -3 | -3 | -4 | -3 | -3 | -3 | -3 | -2 | -2 | -2 |
| Dividend Paid ⓘ | -1 | -1 | -1 | 0 | -1 | -1 | -1 | 0 | 0 | -1 |
| Others ⓘ | 0 | -1 | -2 | -3 | 2 | 0 | -10 | -7 | -13 | -17 |
| Net Cash Flow ⓘ | -3 | -1 | 0 | 0 | 0 | 2 | 2 | 15 | 7 | -1 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 14.05 | 26.67 | 0.16 | 27.78 | 21.02 | 29.55 | 26.91 | -2.6 | 36.29 | 38.56 |
| ROCE (%) | 16.58 | 18.81 | 7.7 | 28.26 | 31.7 | 34.3 | 39.87 | 16.92 | 42.4 | 42.98 |
| Asset Turnover Ratio | 1.73 | 1.77 | 1.8 | 1.8 | 1.73 | 1.57 | 1.23 | 0.84 | 0.8 | 0.71 |
| PAT to CFO Conversion(x) | 6 | 2.33 | N/A | 2.86 | 2.71 | 2.08 | 2.79 | N/A | 2.38 | 1.89 | Working Capital Days |
| Receivable Days | 16 | 18 | 20 | 19 | 16 | 17 | 16 | 20 | 16 | 13 |
| Inventory Days | 25 | 28 | 27 | 20 | 16 | 15 | 15 | 17 | 10 | 8 |
| Payable Days | 138 | 307 | 345 | 321 | 316 | 313 | 239 | 352 | 347 | 321 |
Dr.Agarwal's Eye Hospital has been promoted by Dr.J.Agarwal and his family members in 1994. Though the entire family has been in the profession of providing total eye care solutions for almost five decades prior to this, through various private limited company and partnership firms, owned by the family members. The Hospital has always been at the forefront of every medical advancement in the field of Ophthalmic care in the world and has several firsts to its credit. The Hospital is engaged in conducting continuous training and research and development programs and has over a period, developed an excellent team of highly skilled Ophthalmic specialists and surgeons, to assist in its growth plans.
The Hospital, after notching up an impressive success in TamilNadu, Anthra Pradesh and Rajasthan, is embarking on a major expansion program to increase its footprint to other parts of the country and renovation of its flagship facility at Chennai.
Dr. Agarwal's Eye Hospital is listed as 'A Major Eye Centre of the World' by The International Congress of Ophthalmology
Services offered by the company:
Achievements/ recognition:-
1997:Prof.Amar Agarwal awarded at Coimbatore on 17/08/1997 for the CME conference speaking on lasik laser.
1998:Siva Reddy AwardProf.Amar Agarwal awarded at trichur-30.08.98- by the kerala state ophthalmic conference for the best paper award- on favit- a new technique to remove dropped nuclei.
2003:Sandeep Wagh Gold MedalProf.Amar Agarwal awarded BY Pune Opthalmic Society and national institute of Opthalmology for his invention of PHAKONIT at Pune on 24th Aug 2003.
L V Pasricha Gold MedalProf. Amar Agarwal awarded by Haryana Opthalmic academy at the 18th anual conference at Haryana Opthalmic conference,Karnal on 25th May 2003 by Hon'ble shri.I D Swami, Minister of state of Home Affairs for the invention of Phakonit Technique.
2005:Outstanding Achievement AwardProf.Amar Agarwal awarded by Bombay ophthalmological association for his invention of microphakonit.This award was presented to him during their annual conference held from 4-6 November 2005 at Mumbai.
2006:Padmabushan Award Prof.Dr.J.Agarwal Receiving Padmabushan award from Hon'ble Dr.J.Abdul Kalam,President of India.
Rajiv Gandhi / G K Moopanar AwardProf.Amar Agarwal awarded by hon'ble union minister of state Mr.G.K.Vasan for his invention of mocrophanpkit.This award was presented to him during a meeting held on 26th aug.2006 at Chennai.
2007:Champion of Humanity AwardProf.Amar Agarwal awarded by Hindustan chamber of commerce for his contribution towards community ophthalmology. This was presented to him by mr.vijaikumar bafna, president – Hindustan chamber of commerce on 2nd November 2007 at Chennai.
2008:Gold MedalProf.Amar Agarwal awarded the GOLD MEDAL by Bombay ophthalmic association at Mumbai on 20th September 2008. This was given to him for his new innovation – glued iol.
Scientific Innovation AwardProf. Amar Agarwal awarded by the south Asian academy of opthalmology congress at Delhi on 23rd August 2008. This was awarded to him for his innovations in opthalmology.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
